OPEN CFDA 93.073 ↗ Competitive Cooperative Agreement Hard ~100h to apply

Understanding and Promoting Resources and Opportunities for People with Autism and Fragile X and their Families Across the Lifespan

🏛 Centers for Disease Control - NCBDDD

⏰ Deadline
Jun 15, 2026 ⏰ in 14 days
📊 Total program funding
$18M
🎯 Expected awards
11 recipients
📍 Scope
National
📨 Letter of Intent
Yesrequired first

Can you apply?

This grant is for research organizations studying autism and Fragile X Syndrome. Applicants must have documented access to study participants from the SEED phases 1-3, either as original data collectors or through collaborative agreements. For Fragile X components, applicants need access to clinic-based samples of 200+ individuals ages 0-40 with full mutation diagnosis. Organizations must demonstrate capacity to collect survey data, manage centralized platforms, and disseminate public health findings.

Geographic scope is national. Both nonprofit and government research institutions are eligible. This is a cooperative agreement for multi-year data collection and dissemination work.

Eligible applicants
Check your eligibility — what type of organization are you?

This grant is for research organizations studying autism and Fragile X Syndrome. Applicants must have documented access to study participants from the SEED phases 1-3, either as original data collectors or through collaborative agreements. For Fragile X components, applicants need access to clinic-based samples of 200+ individuals ages 0-40 with full mutation diagnosis. Organizations must demonstrate capacity to collect survey data, manage centralized platforms, and disseminate public health findings.

Geographic scope is national. Both nonprofit and government research institutions are eligible. This is a cooperative agreement for multi-year data collection and dissemination work.

Program description

The goal of this NOFO is to gather unique information not collected by other federal programs to gain a better understanding of the resources (e.g., services, supports) and opportunities (e.g., education, employment, housing, social participation) needed to reduce morbidity, mortality, and economic impacts and improve other long-term outcomes for people with autism or Fragile X Syndrome (FXS) across the lifespan. CDC proposes to implement three components in this NOFO.Component A: Survey to Promote Resources and Opportunities for aUtistic Teens and young adults (SPROUT) will utilize cohorts from the Study to Explore Early Development (SEED) Phases 1-3 (collected from 2007-2020), which were case-control studies of autism in children 2-5 years of age. Participants will range from about 10-25 years of age when this NOFO is awarded. SPROUT will be comprised of caregiver and self-report surveys intended to offer unique information on (1) service and support needs and the impact of co-occurring conditions on autistic people and their families and (2) the educational, transitional, social, and/or vocational needs and experiences of autistic adolescents and young adults. Information from these surveys will be used to improve the health and wellbeing of autistic people and their families. These activities are intended to provide data to inform ways to lessen individual, familial, and societal costs associated with autism, reduce morbidity and mortality, and improve health and well-being.Component B: Focus on Advancing Support and Transition with the Fragile X Online Registry With Accessible Research Database (FAST FORWARD) awardees will employ clinic-based enrollment of eligible participants with a recruitment goal of at least 200 eligible persons with FXS per clinic. Similar to SPROUT, awardees will collect data on (1) timing of and barriers to diagnosis, (2) service and support needs and the impact of co-occurring conditions on people with FXS and their families and (3) the educational, transitional, social, and/or vocational needs and experiences of people with FXS and their families. Awardees will participate in project meetings, recruit participants, collect data, record data in a centralized platform, and produce quality public health products. These activities are intended to provide data to inform ways to lessen individual, familial, and societal costs associated with FXS, reduce morbidity and mortality, and improve health and well-being. Component C: The purpose of this component is to disseminate quality public health products that can improve the health and wellbeing of people with FXS and their families. The awardee will participate in project meetings, develop materials, and disseminate materials to relevant audiences to strengthen the capacity among healthcare providers to appropriately support patients with FXS on a national level.

Who can apply

Eligible applicants

Demographic focus

Details

This grant is for research organizations studying autism and Fragile X Syndrome. Applicants must have documented access to study participants from the SEED phases 1-3, either as original data collectors or through collaborative agreements. For Fragile X components, applicants need access to clinic-based samples of 200+ individuals ages 0-40 with full mutation diagnosis. Organizations must demonstrate capacity to collect survey data, manage centralized platforms, and disseminate public health findings.

Geographic scope is national. Both nonprofit and government research institutions are eligible. This is a cooperative agreement for multi-year data collection and dissemination work.

How to apply

Application links

Required documents

  • SF-424 (Federal Application for Grants and Cooperative Agreements)
  • Project Narrative
  • Budget and Budget Justification
  • Evidence of access to SEED data or collaboration agreements
  • Clinic letters of commitment (Component B)
  • Data management and quality assurance plan
  • Biographical sketches of key personnel

Program contact

  • 👤 Centers for Disease Control - NCBDDD
  • 📧 cvk9@cdc.gov
  • 📞 7704882756

Funding track record

Recent awards under CFDA 93.073 from the last 3 years — real organizations that won funding through this same program.

98
awards (3 yrs)
$221M
total funded
68
unique recipients
$2.3M
average award

Top 10 Largest Recent Awards

  1. $18,009,899
  2. $7,345,638
  3. $6,409,319
  4. $5,459,249
  5. $5,243,171
  6. $5,086,576
  7. $4,692,268
  8. $4,591,432
  9. $4,295,000
  10. $4,250,000

Top States by Funding

  • IL 5 awards $26.6M
  • MD 4 awards $17.1M
  • NY 5 awards $15.0M
  • MA 6 awards $14.2M
  • NC 6 awards $13.9M

Source: USAspending.gov — federal spending transparency. Data covers last 3 years.

Funding history

Annual funding for this program — Federal obligations (CFDA 93.073). How funding has trended year over year.

2024 $59,997,073
2025 $66,807,866
2026 est. $66,807,866

FAQ

Can my organization apply if we didn't originally collect SEED data?

Yes, if you have a formal collaboration agreement with a former SEED data collector who will provide participant contact information.

What if we only want to apply for one component (like Component C)?

You may apply for individual components if you meet eligibility requirements for that specific component only.

How many participants must we recruit for Component B?

You must demonstrate ability to recruit a minimum of 200 unique individuals with Fragile X full mutation diagnosis per clinic location.

Is this primarily a research grant or a service delivery grant?

This is primarily a research and data collection grant focused on understanding service needs and outcomes, not direct service provision.

What is the typical award size?

Total funding pool is $18 million across all awardees; individual award amounts are not specified in this NOFO.

💡 Tips for applicants

  • Clearly document your access to SEED participants or show a signed collaboration agreement with original SEED awardees before applying for Component A.
  • For Component B, provide letters of commitment from clinics confirming they can enroll 200+ FXS patients and participate in data collection activities.
  • Emphasize your infrastructure for secure data management and use of centralized platforms to track enrollment and data quality.
  • For all components, highlight your team's experience with longitudinal research, survey administration, and public health dissemination.
  • Connect your proposed work explicitly to reducing morbidity, mortality, and economic burden for autism and FXS populations.

⚠️ Common mistakes

Applying for Component A without verified access to SEED participant data or formal collaboration agreements with original collectors. Not demonstrating sufficient clinic infrastructure or capacity to recruit 200+ FXS patients for Component B. Weak or vague plans for data management, quality assurance, and centralized platform use.

Similar grants

14 days left Jun 15, 2026
Apply →